According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
Some courts have invalidated AI-related patents where the claims and specification of the patent lacked sufficient specificity regarding the invention.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Most drugs named are biologics, and manufacturing trade secrets make competition especially tricky, legal expert says.
A vast number of healthcare regulatory burdens and intellectual property issues – many of which are frequently overlooked – can snag young digital health companies and either destroy their potential or severely delay them.
A ruling on the high-profile CRISPR patent interference case was delivered Wednesday, sending Editas shares up and causing others to dive. For all involved, the show will go on as other CRISPR licensing agreements still stand.
Four companies from the UC-Berkeley side of the CRISPR patent interference case have signed an alliance to recognize each other's rights to the technology. The agreement highlights the potential for many companies to coexist in the expansive CRISPR field.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Also, CDC approves trial of experimental Zika vaccine, Circassia Pharmaceuticals' cat allergy treatment fails and AI helps reduce misdiagnosis of breast cancer.
If Google is able to overcome the many hurdles to bringing this device to market, it could revolutionize the eye care industry. “What’s in their patent is the Holy Grail for patients over 40 years old," said Dr. Jeffrey Sonsino, an optometrist in Nashville, Tennessee.
This will be a year in which generic drugmakers will have plenty of fodder - more than two dozen major drugs are going off-patent in 2016.
“Patents are one of the most painful parts of running a startup.” That was one of the responses Colleen Chien, an associate professor of Law at Santa Clare Law, got when she surveyed and interviewed some 300 venture capitalists and venture-backed startups in healthcare and tech to understand what patent issues were troubling them. Momentum […]
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Five startups have been selected to join the incubator program at The Fogarty Institute, an education nonprofit based in Mountain Valley, Calif., that mentors medical innovators. Four out of five of these companies–First Pulse Medical, Materna Medical, InPress Technologies and Medical Cue–are attempting to innovate in the maternity/women’s health field. President and CEO Ann Fyfe […]
Great Lakes NeuroTechnologies, a Cleveland-area company that promised more focus on DBS treatments as well as new products this year, has expanded its intellectual property in that area. The patent covers a wearable apparatus that positions an array of electrodes on the surface of the scalp and provides low-dose stimulation to the brain using […]
Passed in September 2011, the final phases of the America Invents Act went into effect in March. Cyrus Morton, a partner at the Minneapolis office of Robins, Kaplan, Miller & Ciresi said this law represents the biggest change since the 1950s. “This bill spent eight years in Congress and finally got passed when this administration […]